Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were 18 years of age or older when they were diagnosed with a specific type of blood cancer called Ph+ CML in chronic phase.
- People who are currently receiving one of these medications as part of their regular medical care: asciminib, bosutinib, dasatinib, imatinib, or nilotinib — either as their first treatment or after having tried one previous medication of the same type.
- People who are receiving their treatment at a medical practice located in the United States or US territories such as Puerto Rico (including community clinics, private offices, hospitals, or academic medical centers).
- People who are willing to sign a consent form agreeing to take part in the study, including allowing their anonymized health records and/or insurance claims data to be used for research purposes.
Who may not be able to join:
- People who are currently participating in another clinical trial that involves a treatment that could affect how their blood cancer is being managed.
- People who are currently on their third or later round of this type of medication (meaning two or more previous medications of this type have already been tried and changed).
- People who are known to have a specific genetic change called the T315I mutation (confirm with trial site).
- People who have finished active treatment and are in a monitored "treatment-free" phase, no longer taking medication for their blood cancer.
- People who have previously undergone a stem cell transplant.
- People who are currently pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals
Phone: 1-888-669-6682
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Rate of discontinuation of index TKI due to AEs
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.